BIBLIOGRAFÍA

Alan L MD, Sandy K, Roe D, Buresh A, Mahadevan D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-7
Alessandrino E, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, Saglio G, Visani G, Tura S. Myelodysplastic syndromes: recent avances.Haematology 2001;86:1124-57
Barret AJ, Savani BN. Allogeneitstem cell transplantion for myelodisplastic syndrome. Semin Hematol 2008;45: 49-59
Bennet JM. Consensus statement on iron overload in myelosplastic syndromes. AM J Hematol 2008; 83: 858-861
Blum W, Klisovic RB, Hackanson B, Phase I study decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007; 25: 3884-3891
Greenberg P. syndrome mielodiaplásico. Revista de Hematología. 2010; 1 (supl.1): 24-25
Ingram W, Lim ZY, Mufti GJ. Allogeneic stem cell transplantion for myelodisplastic syndrome (MSD). Blood Rev 2007; 21:61-71
Kantarijian H, O brien S, Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounta for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113:1351-1361
List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis, J. Efficacy of Lenalidomide in Myelodysplasia Syndromes. N Engl J Med 2005; 352: 549-557
Melchert M,List A. Targeted therapies in myelodisplastic syndrome. Semin Hematol 2008; 45: 31-38
Martin J, Scott M, Ingunn D et al. Long-term EPO and G-CSF treatment of MDS. Blood 2005; 16 (3): 803-11
Margaretn T. Kasner, Selina M. Luger. Update on the therapy for myelodysplastic syndrome. Am J. Hematol. 2009; 84:177-186
Stefan F, Hagop M K. Novel therapies for myelodysplastics syndromes. Cancer 2004; 10 (2): 226-41
Such E, Cervera J, Dolors C. Cytogenetic Risk Stratification in chronic myelomonocyte leukaemia. 2011; 96(3):375-383